Physician profile
Ryan C Knopp
NPI 1427003409
$864.61
in general payments reported to CMS, 2019-2025
22 companies · $76.71 in 2025
The $76.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $138 · 2021: $168 · 2022: $98.78 · 2023: $40.18 · 2024: $17.89 · 2025: $76.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $173.19 | 2019-2023 | |
| Allergan, INC. | $113.15 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.52 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.34 | 2025 | Caplyta |
| Novo Nordisk INC | $57.21 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.24 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $40.64 | 2019-2021 | |
| Amgen INC. | $38.52 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.31 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.93 | 2019 | |
| Eisai INC. | $19.86 | 2021 | |
| Abbott Laboratories | $19.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.05 | 2019 | |
| Glaxosmithkline, LLC. | $17.89 | 2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $16.90 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.60 | 2019 | |
| Grifols USA, LLC | $15.69 | 2019 | |
| Astellas Pharma US INC | $13.41 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.55 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.08 | 2019 | |
| Lilly USA, LLC | $11.67 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Knopp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.